Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioXcel Therapeutics, Inc.BTAI · Entity 8380 | See Remarks | June 15, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioXcel Therapeutics, Inc.
Report date June 15, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,838 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Exercise / conversion · Acquired 35 · Balance 26,838 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 212 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Exercise / conversion · Disposed 35 · Balance 212 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2: On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2024 Filed Jun 19, 2024 01:25 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 521 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-073001 · tm2417544-4_4seq1.xml · derivative · entry 4 Rodriguez Javier · CIK 0001847919 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,648 Underlying: Common Stock · 521 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F3 · derivative.expiration_date: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| June 14, 2024 Filed Jun 19, 2024 01:25 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 521 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-073001 · tm2417544-4_4seq1.xml · nonDerivative · entry 1 Rodriguez Javier · CIK 0001847919 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,193 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 23:30 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 1,012 | $2.64 | $2,667.43 |
DisclosureSEC source: 0001104659-24-044858 · tm2411220-2_4seq1.xml · nonDerivative · entry 3 Rodriguez Javier · CIK 0001847919 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,672 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023. F3 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $2.625 to $2.654. The Reporting Person undertakes to provide upon request the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 15, 2024 Filed Apr 8, 2024 23:30 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-044858 · tm2411220-2_4seq1.xml · derivative · entry 5 Rodriguez Javier · CIK 0001847919 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,750 Underlying: Common Stock · 2,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: On March 15, 2023, the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F5 · derivative.expiration_date: On March 15, 2023, the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| March 15, 2024 Filed Apr 8, 2024 23:30 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 2,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-044858 · tm2411220-2_4seq1.xml · nonDerivative · entry 2 Rodriguez Javier · CIK 0001847919 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| March 14, 2024 Filed Apr 8, 2024 23:30 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 521 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-044858 · tm2411220-2_4seq1.xml · derivative · entry 4 Rodriguez Javier · CIK 0001847919 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,169 Underlying: Common Stock · 521 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F4 · derivative.expiration_date: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| March 14, 2024 Filed Apr 8, 2024 23:30 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 521 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-044858 · tm2411220-2_4seq1.xml · nonDerivative · entry 1 Rodriguez Javier · CIK 0001847919 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 21:54 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 521 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-126923 · tm2333119-3_4seq1.xml · derivative · entry 2 Rodriguez Javier · CIK 0001847919 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,690 Underlying: Common Stock · 521 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F2 · derivative.expiration_date: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 21:54 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 521 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-126923 · tm2333119-3_4seq1.xml · nonDerivative · entry 1 Rodriguez Javier · CIK 0001847919 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 20:48 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 521 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-101639 · tm2326350d2_4seq1.xml · derivative · entry 2 Rodriguez Javier · CIK 0001847919 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,211 Underlying: Common Stock · 521 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F2 · derivative.expiration_date: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| September 14, 2023 Filed Sep 18, 2023 20:48 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 521 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-101639 · tm2326350d2_4seq1.xml · nonDerivative · entry 1 Rodriguez Javier · CIK 0001847919 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 22:46 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 521 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-072399 · tm2319006-5_4seq1.xml · derivative · entry 2 Rodriguez Javier · CIK 0001847919 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,732 Underlying: Common Stock · 521 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F2 · derivative.expiration_date: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 22:46 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 521 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-072399 · tm2319006-5_4seq1.xml · nonDerivative · entry 1 Rodriguez Javier · CIK 0001847919 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 15, 2023 Filed May 17, 2023 00:29 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 1,785 | $27.32 | $48,764.77 |
DisclosureSEC source: 0001104659-23-061537 · tm2316022-1_4seq1.xml · nonDerivative · entry 2 Rodriguez Javier · CIK 0001847919 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,350 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2022. F3 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $27.00 to $27.63. The Reporting Person undertakes to provide upon request the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 14, 2023 Filed May 17, 2023 00:29 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-061537 · tm2316022-1_4seq1.xml · derivative · entry 3 Rodriguez Javier · CIK 0001847919 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On May 14, 2022, the Reporting Person was granted 5,000 RSUs that vested and settled on May 14, 2023. F4 · derivative.expiration_date: On May 14, 2022, the Reporting Person was granted 5,000 RSUs that vested and settled on May 14, 2023. Read SEC document |
| May 14, 2023 Filed May 17, 2023 00:29 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-061537 · tm2316022-1_4seq1.xml · nonDerivative · entry 1 Rodriguez Javier · CIK 0001847919 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,135 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| March 15, 2023 Filed Mar 16, 2023 21:58 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $19.60 | $0.00 |
DisclosureSEC source: 0001104659-23-033400 · tm239796-1_4seq1.xml · derivative · entry 5 Rodriguez Javier · CIK 0001847919 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2033-03-15 F5 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of March 15, 2023 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| March 15, 2023 Filed Mar 16, 2023 21:58 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantRestricted Stock Units · Derivative | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-033400 · tm239796-1_4seq1.xml · derivative · entry 4 Rodriguez Javier · CIK 0001847919 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F4 · derivative.expiration_date: The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| March 15, 2023 Filed Mar 16, 2023 21:58 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | SaleCommon Stock | 950 | $19.63 | $18,643.75 |
DisclosureSEC source: 0001104659-23-033400 · tm239796-1_4seq1.xml · nonDerivative · entry 2 Rodriguez Javier · CIK 0001847919 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,135 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2022. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 21:58 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 2,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-033400 · tm239796-1_4seq1.xml · derivative · entry 3 Rodriguez Javier · CIK 0001847919 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,253 Underlying: Common Stock · 2,084 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F3 · derivative.expiration_date: On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 21:58 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 2,084 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-033400 · tm239796-1_4seq1.xml · nonDerivative · entry 1 Rodriguez Javier · CIK 0001847919 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,084 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 14, 2022 Filed May 17, 2022 19:38 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-061918 · tm2215808-1_4seq1.xml · derivative · entry 1 Rodriguez Javier · CIK 0001847919 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest and settle on May 14, 2023, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest and settle on May 14, 2023, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest and settle on May 14, 2023, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 20:18 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 33,350 | $0.00 Strike: $15.31 | $0.00 |
DisclosureSEC source: 0001104659-22-034503 · tm229449-4_4seq1.xml · derivative · entry 2 Rodriguez Javier · CIK 0001847919 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,350 Underlying: Common Stock · 33,350 shares Expires 2032-03-14 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of March 14, 2022 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 20:18 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantRestricted Stock Units · Derivative | 8,337 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-034503 · tm229449-4_4seq1.xml · derivative · entry 1 Rodriguez Javier · CIK 0001847919 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,337 Underlying: Common Stock · 8,337 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. F2 · derivative.expiration_date: The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 21:27 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $23.84 | $0.00 |
DisclosureSEC source: 0001104659-21-107407 · tm2125392-2_4seq1.xml · derivative · entry 1 Rodriguez Javier · CIK 0001847919 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-08-16 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of August 16, 2021 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 23:59 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $54.90 | $0.00 |
DisclosureSEC source: 0001104659-21-027680 · tm217124-4_4seq1.xml · derivative · entry 1 Rodriguez Javier · CIK 0001847919 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2031-02-21 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of February 22, 2021 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.